CD8A and neoplasm: Bispecific T cell engager (BiTE) is a double scFv-containing molecule that binds concomitantly to CD3 and a tumor-specific antigen, facilitating T cell/cancer cell crosslinking, followed by CD4+/CD8+ T cell activation.